Karuna Therapeutics, Inc. (KRTX)
Stock Price:
$82.50 USD
2.53 (3.16%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
2.20B |
| Revenue (ttm) |
n/a |
| Net Income (ttm) |
-42.52M |
| Shares Out |
26.62M |
| EPS (ttm) |
-1.90 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 27, 2020 |
| Last Price |
$82.50 |
| Previous Close |
$79.97 |
| Change ($) |
2.53 |
| Change (%) |
3.16% |
| Day's Open |
80.03 |
| Day's Range |
79.55 - 83.31 |
| Day's Volume |
97,595 |
| 52-Week Range |
12.48 - 152.00 |
More Stats
| Market Cap |
2.20B |
| Enterprise Value |
1.83B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
26.62M |
| Float |
17.42M |
| EPS (basic) |
-0.38 |
| EPS (diluted) |
-1.90 |
| FCF / Share |
-1.51 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
1.55M |
| Short Ratio |
7.49 |
| Short % of Float |
8.93% |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
n/a |
| PB Ratio |
5.78 |
| Revenue |
n/a |
| Operating Income |
-46.64M |
| Net Income |
-42.52M |
| Free Cash Flow |
-39.64M |
| Net Cash |
365.12M |
| Net Cash / Share |
13.72 |
| Gross Margin |
n/a |
| Operating Margin |
n/a |
| Profit Margin |
n/a |
| FCF Margin |
n/a |
| ROA |
-12.75% |
| ROE |
-18.95% |
| ROIC |
-23.30% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (11)
| Buy |
11 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$124.18*
(50.52% upside)
Low
107
Current: $82.50
High
135
Target: 124.18
*Average 12-month price target from 11 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 |
|---|
| Revenue | - | - | - |
| Operating Income | -45.41 | -14.51 | -4.81 |
| Net Income | -43.96 | -17.51 | -6.03 |
| Shares Outstanding | 11.96 | - | - |
| Earnings Per Share | -3.68 | -4,378,000.00 | - |
| Operating Cash Flow | -30.92 | -15.38 | -4.03 |
| Capital Expenditures | -0.12 | -0.13 | -0.01 |
| Free Cash Flow | -31.04 | -15.51 | -4.04 |
| Cash & Equivalents | 390 | 14.01 | 1.94 |
| Total Debt | 0.21 | 2.52 | 11.66 |
| Net Cash / Debt | 389 | 11.49 | -9.72 |
| Assets | 393 | 15.86 | 2.13 |
| Liabilities | 3.11 | 3.81 | 15.50 |
| Book Value | 390 | -29.92 | -13.37 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Karuna Therapeutics, Inc. |
| Country |
United States |
| Employees |
19 |
| CEO |
Steven Marc Paul |
Stock Information
| Ticker Symbol |
KRTX |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Biotechnology |
| Unique Identifier |
NASDAQ: KRTX |
| IPO Date |
June 28, 2019 |
Description
Karuna Therapeutics, a clinical-stage biopharmaceutical company, primarily focuses on developing novel therapies to address disabling neuropsychiatric disorders and pain. Its lead product candidate is KarXT, an oral modulator that has completed Phase II clinical trial for the treatment of acute psychosis in patients with schizophrenia; and in Phase Ib clinical trial for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, Alzheimer's, and pain, as well as for the treatment of dementia-related psychosis. The company also focuses on developing other muscarinic-targeted drug candidates. Karuna Therapeutics, Inc. has a license agreement with Eli Lilly and Company; patent license agreement with PureTech Health LLC; and drug discovery partnership with Charles River Laboratories, as well as drug discovery collaboration with PsychoGenics Inc. The company was formerly known as Karuna Pharmaceuticals, Inc. and changed its name to Karuna Therapeutics, Inc. in March 2019. Karuna Therapeutics, Inc. was founded in 2009 and is headquartered in Boston, Massachusetts.